• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » J&J focuses on strengthening MedTech business, dampens M&A talk

J&J focuses on strengthening MedTech business, dampens M&A talk

July 20, 2022 By Sean Whooley

Johnson & Johnson MedTechJohnson & Johnson (NYSE:JNJ) CEO Joaquin Duato says the company isn’t harping on mergers and acquisitions as it grows its MedTech business.

Speaking on the company’s second-quarter earnings call, Duato emphasized that Johnson & Johnson MedTech, its rebranded medical devices business, has its sights set on strengthening current strongholds and accessing high-growth market segments to accelerate its own growth.

“When it comes to MedTech, the focus continues to be strengthening our current strongholds and also accessing some high-growth market segments to accelerate growth,” Duato said on the call, as transcribed by The Motley Fool. “And the target areas are the ones that we are operating today: high health orthopedics, cardiology, surgery, historically, it’s been a predictor of our success to the extent we were closer to the areas that we have capabilities.”

Johnson & Johnson MedTech saw a 1.1% decrease in sales for the quarter, pulling in nearly $6.9 billion in revenues for the three-month period. The company’s adjusted operational sales grew 3.4%, driven primarily by contact lenses and surgical vision products, as well as electrophysiology products.

Despite recent suggestions from analysts — and company officials themselves at the end of the first quarter — that Johnson & Johnson was looking to get active on the M&A front, with Boston Scientific suggested as one realistic option, Duato stressed that the company takes a “strategic approach,” looking at improvements in the standard of care that the company is eyeing. While playing down any rumored eagerness to make acquisitions, Duato still emphasized that opportunities do exist on the market.

“As we look at the opportunities today in the market, we are not opportunistic about it, and we are still looking always at the fundamentals of these companies,” Duato said. “And, obviously, there are different opportunities in the market that are interesting and can complement our existing franchises or built into adjacencies.”

Duato added, “Down the road, we continue to see M&A as an important source of building our pipeline and also fortifying our current portfolio, and we are now in a position that, for the first time… in the last five years, we’re in a cash-neutral position. And we continue to look at the opportunities that are out there, and we’ll continue to do it.”

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Mergers & Acquisitions, News Well, Wall Street Beat Tagged With: Johnson & Johnson, Johnson & Johnson MedTech

More recent news

  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year
  • Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy